Valuation of a Biotechnology Firm: An application of real-options methodologies

Explore this paper's citation graph

Summary

Much of the value contained in early stages of pharmaceutical projects is in the promise of developing a blockbuster drug, and firms in the biotechnology industry have significant valuations, yet do not have profits from which to value the firm using traditional methods.

Type
article
Published
1999-01-01
Cited by
23
References
17

Keywords

Valuation (finance), Discounted cash flow, Cash flow, Business, Pharmaceutical industry

References

Cited by

Related papers